Join
Live feed
·
PRReleasevia Quantisnow
Myriad Genetics Inc. logo

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

ByQuantisnow·Wall Street's wire, on your screen.
MYGN· Myriad Genetics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MYGN (Myriad Genetics Inc.) and more on Quantisnow.